South Carolina Mesothelioma Fact Sheet
While mesothelioma is a problem in all states, the specific incident rate for South Carolina is 0.8 / 100,000. This is below the average rate of 1.1 / 100,000. Click on the tabs below to find mesothelioma and asbestos research in SC, recent SC mesothelioma-related court cases, mesothelioma specialists in SC and potential asbestos hotspots in South Carolina.
South Carolina Mesothelioma Info
By clicking on the above tabs, you will find information on mesothelioma specific to the state of South Carolina
South Carolina Research and Clinical Trials
This is a partial list of scientific or medical grants in your state for research into mesothelioma and related illnesses.
South Carolina Doctors and Hospitals
This is a partial list of hospitals and physicians that reportedly treat mesothelioma patients in your state.
South Carolina Cases
This is a partial list of relevant court cases on mesothelioma in your state.
Disclaimer: Inclusion on this directory does not constitute endorsement by Cancer Monthly, Inc. All physicians who appear in this section do so based on their own expression of interest in the fields of mesothelioma treatment. Cancer Monthly, Inc. has not verified the competence, professional credentials, business practices or validity of the expressed interests of these physicians. Cancer Monthly makes no recommendation of any physician on this list and makes no suggestion that any such physician will cure or prevent any disease. Those consulting a physician on this list should approach the consultation exactly as they would with any other unknown physician.
This is a partial list of scientific or medical grants in your state for research into mesothelioma and related illnesses.
South Carolina Doctors and Hospitals
This is a partial list of hospitals and physicians that reportedly treat mesothelioma patients in your state.
South Carolina Cases
This is a partial list of relevant court cases on mesothelioma in your state.
Disclaimer: Inclusion on this directory does not constitute endorsement by Cancer Monthly, Inc. All physicians who appear in this section do so based on their own expression of interest in the fields of mesothelioma treatment. Cancer Monthly, Inc. has not verified the competence, professional credentials, business practices or validity of the expressed interests of these physicians. Cancer Monthly makes no recommendation of any physician on this list and makes no suggestion that any such physician will cure or prevent any disease. Those consulting a physician on this list should approach the consultation exactly as they would with any other unknown physician.
Henderson v. Allied Signal, Inc.
Opinion No. 26322, SUPREME COURT OF SOUTH CAROLINA, March 6, 2007, Heard, April 30, 2007, Filed
Opinion No. 26322, SUPREME COURT OF SOUTH CAROLINA, March 6, 2007, Heard, April 30, 2007, Filed
Murphy v. Owens-Corning Fiberglas Corp.
[NO NUMBER IN ORIGINAL], SUPREME COURT OF SOUTH CAROLINA, December 8, 2003, Decided
[NO NUMBER IN ORIGINAL], SUPREME COURT OF SOUTH CAROLINA, December 8, 2003, Decided
Murphy v. Owens-Corning Fiberglas Corp.
Opinion No. 25740 , SUPREME COURT OF SOUTH CAROLINA, February 6, 2003, Heard February 6, 2003 , October 27, 2003, Filed
Opinion No. 25740 , SUPREME COURT OF SOUTH CAROLINA, February 6, 2003, Heard February 6, 2003 , October 27, 2003, Filed
Murphy v. Owens-Corning Fiberglas Corp.
Opinion No. 3354, COURT OF APPEALS OF SOUTH CAROLINA, November 7, 2000, Heard , June 11, 2001, Filed
Opinion No. 3354, COURT OF APPEALS OF SOUTH CAROLINA, November 7, 2000, Heard , June 11, 2001, Filed
Murphy v. Owens-Corning Fiberglas Corp.
Opinion No. 3203, COURT OF APPEALS OF SOUTH CAROLINA, November 4, 1999, Heard , June 26, 2000, Filed
Opinion No. 3203, COURT OF APPEALS OF SOUTH CAROLINA, November 4, 1999, Heard , June 26, 2000, Filed
Rogers v. Kunja Knitting Mills,U.S.A.
Opinion No. 3029, COURT OF APPEALS OF SOUTH CAROLINA, April 15, 1999, Heard , July 26, 1999, Filed
Opinion No. 3029, COURT OF APPEALS OF SOUTH CAROLINA, April 15, 1999, Heard , July 26, 1999, Filed
Hospitals and Cancer Centers
We do not have any doctors or cancer centers for this state at the moment.
We do not have any doctors or cancer centers for this state at the moment.
| City | Site |
|
Shaw Air Force Base | |
| Aiken |
Atomic Energy Plant |
| Akins |
Savannah River Project |
| Charleston |
Charleston Naval Shipyard Tanners Creek Station US Naval Station |
| Clearwater |
United Merchants |
| Columbia |
Eastman Kodak Trojan Steel VA Hospital |
| Eastover |
Eastover Paper Mill |
| Florence |
Union Carbide |
| Greenville |
Daniel Building |
| Irma |
Allied Chemical |
| Jacksonville |
Camp Geiger Camp Lejune Marine Base |
| Oconee County |
Oconee Nuclear Station |
| Sandy Springs |
Michelin Tire |
| Taylor |
Steele Hedder |
Research
Boylan, Alice M. A Novel Oncogene In Mesothelioma
Grant: 1R01ES011323-01A2
Grant: 1R01ES011323-01A2
Abstract:
DESCRIPTION (provided by applicant): The occupational cancer malignant mesothelioma is newly diagnosed in up to 3,000 persons per year in the US and most of these patients will die within 12 months of diagnosis regardless of treatment. Millions remain at risk in the US and the number at risk is expected to climb in developing nations where asbestos continues to be used, often without protection. In order to significantly impact this disease more needs to be known about the molecular mechanisms required for the initiation and maintenance of the malignant state in the mesothelial cell. Although a number of investigators have described increases in expression of some genes in mesothelioma cells, no oncogenes have been shown to have functional importance. Studies preliminary to this work show that a unique oncogene named CaSm, which is likely to transform cells through its role in RNA message destabilization, has high levels of expression of message and protein in virtually all mesothelioma cell lines and the majority of mesothelioma tumors examined. Further preliminary studies show that antisense CaSm inhibits growth of mesothelioma cells in vitro and in vivo. Antisense CaSm inhibition of growth is associated with cell-specific cell cycle alterations and increased expression of specific cell cycle-associated proteins. From this work we formed the hypothesis that: elevated CaSm expression plays a critical role in the development and maintenance of the malignant phenotype in asbestos-induced malignant mesothelioma To establish the role of CaSm expression in the malignant phenotype of mesothelioma cells, a series of loss of function and gain of function experiments will be performed using sense and antisense strategies, as well as small inhibitory RNAs. Important gain of function experiments will also be performed in vivo through the development of a transgenic mouse which will conditionally express CaSm in a tissue-specific manner. Focus will be placed upon the role of CaSm in regulation of expression of cell cycle proteins. Actinomycin chase and mutation analysis experiments will then be performed to determine if CaSm exerts its effect on cell cycle by destabilizing messages for these proteins. Finally experiments will determine whether asbestos specifically induces the expression of CaSm, and if it does so via reactive oxygen species or via other known mechanisms such as integrin adhesion. We believe these studies will provide exciting information and important insight into this cancer.
Tags: Asbestos, Chemical Related Neoplasm /cancer, Functional /structural Genomics, Gene Expression, Mesothelioma, Neoplasm /cancer Genetics, Oncogene Actinomycin, Cell Cycle Protein, Cell Proliferation, Free Radical Oxygen, Gene Induction /repression, Phenotype 3t3 Cell, Rnase Protection Assay, Scid Mouse, Clinical Research, Human Subject, Transfection /expression Vector, Transgenic Animal
Tags: Asbestos, Chemical Related Neoplasm /cancer, Functional /structural Genomics, Gene Expression, Mesothelioma, Neoplasm /cancer Genetics, Oncogene Actinomycin, Cell Cycle Protein, Cell Proliferation, Free Radical Oxygen, Gene Induction /repression, Phenotype 3t3 Cell, Rnase Protection Assay, Scid Mouse, Clinical Research, Human Subject, Transfection /expression Vector, Transgenic Animal
Role Of A Novel Oncogene In Mesothelioma
Grant:
Grant:
Abstract:
- Followup Grant: 5R01ES011323-03
- Followup Grant: 5R01ES011323-04
- Followup Grant: 5R01ES011323-05
Clinical Trials
Condition: Malignant Mesothelioma
Intervention: Drug: cisplatin; Drug: gemcitabine hydrochloride
More Information
Intervention: Drug: cisplatin; Drug: gemcitabine hydrochloride
More Information
Active, not recruiting Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma
Condition: Malignant Mesothelioma
Intervention: Drug: dasatinib; Other: immunoenzyme technique; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
More Information
Intervention: Drug: dasatinib; Other: immunoenzyme technique; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
More Information
Condition: Malignant Mesothelioma
Intervention: Drug: epirubicin hydrochloride; Drug: gemcitabine hydrochloride
More Information
Intervention: Drug: epirubicin hydrochloride; Drug: gemcitabine hydrochloride
More Information
Have questions about mesothelioma?
If you want answers right now call our Mesothelioma Resource Specialist - Abby Palmer, MSW.
She takes calls throughout the day and early evening. Her number is: 619-261-7922.
She is not a doctor and does not provide medical advice.
DISCLAIMER: Surviving Mesothelioma® is registered with the United States Patent and Trademark Office by Cancer Monthly, Inc. and the website is owned and managed by Cancer Monthly Inc. All of the information provided on this website is for informational purposes only. Neither Cancer Monthly nor this website renders medical advice or professional services. The information provided by Abby Palmer or any other employee or contractor of Cancer Monthly, Inc. is not to be considered medical advice and is not intended to replace consultation with a qualified medical professional. You should consult a qualified health care provider for medical advice and answers to personal health questions. The responsibility of your disease management plan is with your treating physicians and you should only follow your treating physician’s advice. DO NOT change or modify your disease management plan on your own without consulting your treating physicians. This website is not a substitute for professional medical advice, examination, diagnosis or treatment. This website should not be used for diagnosing or treating a health problem or disease and it is not a substitute for professional care. You should always seek the advice of your physician or other qualified health professional before starting any new treatment or making any changes to an existing treatment. You should not delay in seeking or disregard medical advice based on information on this website. Some information may be out of date. The information on this website is intended to convey general information only. It should not be construed as legal advice or opinion. This website and its contents are not intended to create an attorney-client relationship. You should not act on or rely on any information on this website without seeking the advice of an attorney. You are encouraged to promptly speak to legal counsel to identify and protect your legal rights and any deadlines for filing a claim or lawsuit. People who request a free book may be called to verify their address and to introduce other mesothelioma resources that are available.
